Swiss pharmaceutical and biotech ingredient supplier Lonza (VTX: LONN) says it will establish Centers of Excellence for Cell and Gene Therapy to support and accelerate the growth of this priority area for the company.
This decision advances Lonza's strategy of being one of the world’s leading, integrated, value-added solutions providers along the healthcare continuum, the company explains. To further improve its support to customers, Lonza’s Cell- and Gene-Therapy Centers of Excellence will include Lonza sites that are already serving customers and their patients with these innovative technologies.
The Lonza sites in Pearland, Texas (USA) and Geleen/Maastricht (Netherlands) will offer a fully integrated range of cell- and gene-therapy services including process and analytical development, clinical product supply and commercial product supply. Lonza’s sites in Portsmouth, New Hampshire (USA) and Singapore will serve both as clinical and commercial manufacturing sites.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze